Stock Spotlight: EBOS Group Ltd (ASX:EBO)

About EBOS Group Ltd

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.

Key Stats

Source: Yahoo Finance. Data as of 05/09/25.

Growth Potential

• Recent share price correction has resulted in EBO’s valuation looking more attractive along with offering a solid dividend yield.
• While EBO earnings are not completely immune to economic conditions, we do believe there are elements of defensive quality to EBO’s earnings which may warrant a premium to the market.
• Leveraged to positive industry trends across healthcare (ageing population + increased pharma & medical spend) and increased pet spend (pet ownership + pert humanization).
• Market leading positions including - pharmaceutical wholesaler (Aus & NZ), community pharmacy network in Australia (TerryWhite Chemmart), ANZ/NZ hospital medicines wholesaler and ANZ’s largest dry dog food brand in pet specialty
• Bolt on acquisitions to supplement organic growth – the Company has a successful history of making acquisitions.
• New contract wins.
  

Key Risks

• Changes to the industry structure or competitive landscape which leads to increased customer churn (loss of contracts).
• Poor execution.
• Value destructive M&A.
• Change in senior management.
• Cut to dividends due to balance sheet or earnings pressure.